Video: Who Am I?| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: Primary care

Updated EULAR Recommendations for Early Arthritis; Plus FDA Approves New Abuse-Deterrent Morphine Sulfate

Michele B. Kaufman, PharmD, BCGP  |  January 25, 2017

EULAR has updated its recommendations for the management of early arthritis, outlining aspects of diagnosis and drug treatments…

Filed under:AnalgesicsConditionsDrug UpdatesEULAR/OtherMeeting ReportsRheumatoid Arthritis Tagged with:Arthritisearly arthritisEULARFDAFood and Drug AdministrationOpioidsrecommendationsTreatment

Guselkumab Improves Active Psoriatic Arthritis

Michele B. Kaufman, PharmD, BCGP, & Lara C. Pullen, PhD  |  January 11, 2017

A study showed that guselkumab may decrease symptoms of psoriatic arthritis and improve quality of life in adult patients…

Filed under:Biologics/DMARDsDrug Updates

FDA Update: FX006 Promising for Knee OA; Pioglitazone Linked to Bladder Cancer Risk; & HIV Drug Gets New Labeling

Michele B. Kaufman, PharmD, BCGP  |  January 4, 2017

The makers of FX006, a steroid injection for treating pain in patients with knee osteoarthritis, have submitted a new drug application to the FDA…

Filed under:AnalgesicsDrug UpdatesOsteoarthritis and Bone Disorders Tagged with:CancerFDAFood and Drug AdministrationFX006HIVkneeKnee Osteoarthritis (OA)Painpioglitazone

Does Telephone Coaching Enhance Physical Activity Programs?

Arthritis Care & Research  |  January 3, 2017

Health coaching by telephone is increasingly being used to assist in chronic disease self-management. A recent study examined the benefits of simultaneous health coaching via telephone as an addition to a physiotherapist-prescribed home-based physical activity program for patients with knee OA. Although participants receiving additional coaching had a short-term improvement in adherence, changes in pain and function did not differ between the study’s groups at six months…

Filed under:ConditionsOsteoarthritis and Bone Disorders Tagged with:Exerciseexercise therapykneeKnee Osteoarthritis (OA)Physical Therapy

Lesinurad with Allopurinol When Allopurinol Alone Is Insufficient

Arthritis & Rheumatology  |  December 29, 2016

Current guidelines for the long-term management of gout recommend a combination of lifestyle management and/or pharmacotherapy to lower serum UA levels to <6.0 mg/dL in most patients or <5.0 mg/dL in patients with more severe disease. Allopurinol is the most widely used xanthine oxidase inhibitor and is recommended in treatment guidelines as a first-line urate-lowering…

Filed under:ConditionsGout and Crystalline ArthritisResearch Rheum Tagged with:AllopurinolArthritis & RheumatologyGoutlesinuradResearchUric acid

Rheumatology Drug Updates: Celecoxib and Cardiovascular Safety Trial Results Reviewed

Michele B. Kaufman, PharmD, BCGP  |  December 13, 2016

Nonsteroidal anti-inflammatory drugs (NSAIDs) have been used therapeutically since the 1960s.1 Evidence of adverse cardiovascular outcomes led to the withdrawal of the selective COX-2 inhibitor rofecoxib in September 2004, when the question of cardiovascular safety of NSAIDs first came into the limelight.2 Valdecoxib (Bextra) was subsequently withdrawn from the market in April 2005 due to…

Filed under:AnalgesicsDrug UpdatesResearch Rheum Tagged with:anti-inflammatorycardiovascularcelecoxib (Elyxyb)drugFDAmortalityNSAIDoutcomePrecision trialResearchrheumatologyriskSafety

Celecoxib & Cardiovascular Death: NSAID Safety Under Review

Michele B. Kaufman, PharmD, BCGP  |  December 7, 2016

A recent study showed that at moderate doses celecoxib may be noninferior with respect to cardiovascular safety compared with ibuprofen or naproxen…

Filed under:AnalgesicsDrug Updates Tagged with:cardiovascularFDAFood and Drug AdministrationheartNSAIDsPREC

Rheumatology Fellowship Work in Ethiopia Reveals Gaps in Practical Management of Rheumatic Diseases

Mary Abraham, MD, MBA, with Frehyiwot Ayele, MD  |  November 16, 2016

The first month of my last year of rheumatology fellowship began in Addis Ababa, Ethiopia, at Black Lion Hospital, a tertiary university medical center, where I [Dr. Mary Abraham] started an Emory-sponsored global health rotation. Although a very different beginning to my fellowship year, my experiences at Black Lion reminded me of my passion to…

Filed under:Rheumatoid Arthritis Tagged with:Black Lion HospitalDr. Frehyiwot AyeleDr. Mary AbrahamEthiopiafellowshipInternationalpatient careresidentrheumatology

Rheumatology Patient, Investigator Reflect on Advancements in Lupus, Rheumatoid Arthritis Treatments

From the College  |  November 16, 2016

In 1969, Martha Lovato passed away from renal failure due to complications of lupus. Martha was 18 years old and survived only two years following her diagnosis. At the time, Martha’s disease was still a mystery to many physicians and researchers. Her treatment options were limited. In fall 2004, after an unprecedented battle with shingles…

Filed under:ConditionsFrom the CollegeResearch RheumRheumatoid ArthritisSystemic Lupus Erythematosus Tagged with:Dr. Amit GoldingLupusMedicationpatient careRheumatoid arthritisRheumatology Research FoundationSLETreatmentYolanda Grundhoffer

2015 Workforce Study Results: More Rheumatology Clinicians Needed

Susan Bernstein  |  October 18, 2016

Will there be enough rheumatology clinicians available to treat a growing patient population in the future? Not unless serious steps are taken now, according to the American College of Rheumatology’s 2015 Workforce Study of Rheumatology Specialists in the United States. The study’s complete findings will be presented at a panel discussion session at the 2016…

Filed under:Professional TopicsWorkforce Tagged with:ACR Workforce Studyrheumatology cliniciansworkforce projections

  • « Previous Page
  • 1
  • …
  • 108
  • 109
  • 110
  • 111
  • 112
  • …
  • 138
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences